Thus, STON2 expression can serve as a predictor of intraperitoneal metastasis and recurrence in EOC patients and can be used to provide more precise cancer staging as well as guide a more radical personalized therapy by more effectively reducing the mortality rate of EOC patients. This evidence concerns the gene STON2 and cancer.